PharmaBlock Sciences Nanjing Inc Class A
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, DNA encoded library technology, and mega virtual lib… Read more
PharmaBlock Sciences Nanjing Inc Class A (300725) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.012x
Based on the latest financial reports, PharmaBlock Sciences Nanjing Inc Class A (300725) has a cash flow conversion efficiency ratio of 0.012x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥83.36 Million) by net assets (CN¥7.15 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PharmaBlock Sciences Nanjing Inc Class A - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how PharmaBlock Sciences Nanjing Inc Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PharmaBlock Sciences Nanjing Inc Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PharmaBlock Sciences Nanjing Inc Class A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wuhan Yangtze Communication Industry Group Co Ltd
SHG:600345
|
-0.001x |
|
Guardian Pharmacy Services, Inc.
NYSE:GRDN
|
0.144x |
|
Central Pacific Financial Corp
NYSE:CPF
|
0.038x |
|
Grg Metrology
SHE:002967
|
0.051x |
|
Kainos Group plc
PINK:KNNNF
|
0.110x |
|
HBM HLDGS LTD DL-000025
F:6XY
|
N/A |
|
Tangshan Jidong Cement Co Ltd
SHE:000401
|
0.029x |
|
EXEDY CORP.
F:64M
|
N/A |
Annual Cash Flow Conversion Efficiency for PharmaBlock Sciences Nanjing Inc Class A (2013–2024)
The table below shows the annual cash flow conversion efficiency of PharmaBlock Sciences Nanjing Inc Class A from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.99 Billion | CN¥302.82 Million | 0.101x | +16.30% |
| 2023-12-31 | CN¥2.83 Billion | CN¥246.84 Million | 0.087x | -6.08% |
| 2022-12-31 | CN¥2.66 Billion | CN¥246.61 Million | 0.093x | +2.44% |
| 2021-12-31 | CN¥2.63 Billion | CN¥238.03 Million | 0.091x | -36.79% |
| 2020-12-31 | CN¥1.89 Billion | CN¥271.51 Million | 0.143x | -16.44% |
| 2019-12-31 | CN¥740.87 Million | CN¥127.04 Million | 0.171x | -35.79% |
| 2018-12-31 | CN¥599.73 Million | CN¥160.16 Million | 0.267x | +146.14% |
| 2017-12-31 | CN¥503.59 Million | CN¥54.64 Million | 0.108x | +21.17% |
| 2016-12-31 | CN¥254.15 Million | CN¥22.76 Million | 0.090x | -52.32% |
| 2015-12-31 | CN¥146.56 Million | CN¥27.52 Million | 0.188x | +37.48% |
| 2014-12-31 | CN¥87.18 Million | CN¥11.91 Million | 0.137x | -47.68% |
| 2013-12-31 | CN¥70.16 Million | CN¥18.32 Million | 0.261x | -- |